NCT04886167

Dysport Dose-Ranging Treatment of Platysmal Bands

A Dose-Ranging Study to Evaluate the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Platysmal Bands

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Clinical Testing of Beverly Hills · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a double-blinded, dose-ranging study in the US to assess the efficacy, safety, and duration of response of abobotulinumtoxinA for the treatment of moderate to severe platysmal bands.

Detailed description

This study is intended to evaluate the efficacy and safety of an initial dose of 120 U, 180 U, and 240 U of abobotulinumtoxinA (with optional touch-up) in the treatment of moderate to severe platysmal bands. The platysmal bands will be treated by intramuscular injection of abobotulinumtoxinA.

Conditions

• Platysma Bands

Interventions

Type	Name	Description
DRUG	AbobotulinumtoxinA	Injection of platysmal bands.

Timeline

• Start date: 2021-05-30
• Primary completion: 2022-11-01
• Completion: 2022-11-01
• First posted: 2021-05-13
• Last updated: 2022-10-12

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study